CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Secukinumab

Last Updated: December 8, 2014
Result type: Reports
Project Number: SR0407-000
Product Line: Common Drug Review

Generic Name: Secukinumab

Brand Name: Cosentyx

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Indications: Psoriasis, moderate to severe plaque

Submission Type: Pre-NOC

Project Status: Complete

Date Recommendation Issued: October 28, 2015

Recommendation Type: List with criteria/condition